|
|
|
Volumn 5, Issue 2, 1999, Pages 289-304
|
|
Response of the pharmaceutical industry to antimicrobial resistance
a
|
|
Author keywords
Antibacterials; Antimicrobial resistance; Bacterial genomics; Bacterial vaccines; Clinical development; Pharmaceutical industry collaborations; Surveillance
|
|
Indexed keywords
AMINOGLYCOSIDE;
AMOXICILLIN;
AMOXICILLIN PLUS CLAVULANIC ACID;
AMPICILLIN;
ANTIBIOTIC AGENT;
ANTIINFECTIVE AGENT;
BETA LACTAM;
CARBENICILLIN;
CEFALEXIN;
CEFALORIDINE;
CEFALOTIN;
CEPHALOSPORIN;
CIPROFLOXACIN;
CLAVULANIC ACID;
CLOXACILLIN;
ENOXACIN;
GLYCOPEPTIDE;
GREPAFLOXACIN;
MACROLIDE;
METICILLIN;
NORFLOXACIN;
OFLOXACIN;
PENICILLIN G;
PIPERACILLIN PLUS TAZOBACTAM;
QUINOLONE;
SULTAMICILLIN;
TICARCILLIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VANCOMYCIN;
ZOCIN;
ANTIBIOTIC RESISTANCE;
BACTERIAL GENETICS;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
DRUG UTILIZATION;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
SCREENING;
|
|
EID: 0032720205
PISSN: 10716564
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (42)
|
